Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update

被引:161
|
作者
Brichta, Lars [1 ]
Greengard, Paul [1 ]
机构
[1] Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10065 USA
来源
FRONTIERS IN NEUROANATOMY | 2014年 / 8卷
关键词
Parkinson's disease; substantia nigra; ventral tegmental area; dopamine; selective vulnerability; differential vulnerability; VENTRAL TEGMENTAL AREA; SUBSTANTIA-NIGRA NEURONS; AMYOTROPHIC-LATERAL-SCLEROSIS; MITOCHONDRIAL-DNA DELETIONS; TRANSLATIONAL PROFILING APPROACH; GENE-EXPRESSION PROFILES; K-ATP CHANNELS; CNS CELL-TYPES; ALPHA-SYNUCLEIN; ALDEHYDE DEHYDROGENASE;
D O I
10.3389/fnana.2014.00152
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Numerous disorders of the central nervous system (CNS) are attributed to the selective death of distinct neuronal cell populations. Interestingly, in many of these conditions, a specific subset of neurons is extremely prone to degeneration while other, very similar neurons are less affected or even spared for many years. In Parkinson's disease (PD), the motor manifestations are primarily linked to the selective, progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). In contrast, the very similar DA neurons in the ventral tegmental area (VIA) demonstrate a much lower degree of degeneration. Elucidating the molecular mechanisms underlying the phenomenon of differential DA vulnerability in PD has proven extremely challenging. Moreover, an increasing number of studies demonstrate that considerable molecular and electrophysiologic heterogeneity exists among the DA neurons within the SNpc as well as those within the VIA, adding yet another layer of complexity to the selective DA vulnerability observed in PD. The discovery of key pathways that regulate this differential susceptibility of DA neurons to degeneration holds great potential for the discovery of novel drug targets and the development of promising neuroprotective treatment strategies. This review provides an update on the molecular basis of the differential vulnerability of midbrain DA neurons in PD and highlights the most recent developments in this field.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease
    Choi, HJ
    Lee, SY
    Cho, Y
    Hwang, OY
    NEUROCHEMISTRY INTERNATIONAL, 2005, 46 (04) : 329 - 335
  • [42] Parkinson's disease: an update on pathogenesis and treatment
    Foltynie, Tom
    Kahan, Joshua
    JOURNAL OF NEUROLOGY, 2013, 260 (05) : 1433 - 1440
  • [43] To what extent may aminochrome increase the vulnerability of dopaminergic neurons in the context of Parkinson's disease
    Chagraoui, Abdeslam
    Anouar, Youssef
    De Deurwaerdere, Philippe
    Arias, Hugo R.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2024, 168
  • [44] Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson's disease
    McCcoy, Bronagh
    Jahfari, Sara
    Engels, Gwenda
    Knapen, Tomas
    Theeuwes, Jan
    BRAIN, 2019, 142 : 3605 - 3620
  • [45] Gender-Related Vulnerability of Dopaminergic Neural Networks in Parkinson's Disease
    Boccalini, Cecilia
    Carli, Giulia
    Pilotto, Andrea
    Padovani, Alessandro
    Perani, Daniela
    BRAIN CONNECTIVITY, 2021, 11 (01) : 3 - 11
  • [46] Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease
    Devos, David
    Defebvre, L.
    Bordet, R.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (04) : 407 - 421
  • [47] Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease
    Goldstein, David S.
    Sullivan, Patti
    Holmes, Courtney
    Miller, Gary W.
    Alter, Shawn
    Strong, Randy
    Mash, Deborah C.
    Kopin, Irwin J.
    Sharabi, Yehonatan
    JOURNAL OF NEUROCHEMISTRY, 2013, 126 (05) : 591 - 603
  • [48] Changes in dopaminergic neurons of the mesocorticolimbic system in Parkinson's disease
    Dymecki, J
    Lechowicz, W
    Bertrand, E
    Szpak, GM
    FOLIA NEUROPATHOLOGICA, 1996, 34 (02) : 102 - 106
  • [49] PUERARIN PROTECTS DOPAMINERGIC NEURONS IN PARKINSON'S DISEASE MODELS
    Zhang, X.
    Xiong, J.
    Liu, S.
    Wang, L.
    Huang, J.
    Liu, L.
    Yang, J.
    Zhang, G.
    Guo, K.
    Zhang, Z.
    Wu, P.
    Wang, D.
    Lin, Z.
    Xiong, N.
    Wang, T.
    NEUROSCIENCE, 2014, 280 : 88 - 98
  • [50] Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics
    Cacabelos, Ramon
    Carrera, Ivan
    Martinez, Olaia
    Alejo, Ramon
    Fernandez-Novoa, Lucia
    Cacabelos, Pablo
    Corzo, Lola
    Rodriguez, Susana
    Alcaraz, Margarita
    Nebril, Laura
    Tellado, Ivan
    Cacabelos, Natalia
    Pego, Rocio
    Naidoo, Vinogran
    Carril, Juan C.
    MEDICINAL RESEARCH REVIEWS, 2021, 41 (05) : 2841 - 2886